The DOI matches its Crossref record.
A Novel Macromolecular Prodrug Concept Exploiting Endogenous Serum Albumin as a Drug Carrier for Cancer Chemotherapy
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVLetterNEXTA Novel Macromolecular Prodrug Concept Exploiting Endogenous Serum Albumin as a Drug Carrier for Cancer ChemotherapyFelix Kratz, Ralph Müller-Driver, Inga Hofmann, Joachim Drevs, and Clemens UngerView Author Information Tumor Biology Center, Breisacher Strasse 117, 79106 Freiburg, Federal Republic of Germany Cite this: J. Med. Chem. 2000, 43, 7, 1253–1256Publication Date (Web):March 10, 2000Publication History Received25 November 1999Published online10 March 2000Published inissue 6 April 2000https://pubs.acs.org/doi/10.1021/jm9905864https://doi.org/10.1021/jm9905864rapid-communicationACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views2407Altmetric-Citations134LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-AlertscloseSupporting Info (1)»Supporting Information Supporting Information SUBJECTS:Anatomy,Antineoplastic agents,Biopolymers,Cancer,Peptides and proteins Get e-Alerts
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
Kratz, F. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.05.010 · Cited by 2,151
Self-citationPolymer Therapeutics: Concepts and Applications
Haag, R., & Kratz, F. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200502113 · Cited by 1,115
Self-citationImpact of albumin on drug delivery — New applications on the horizon
Elsadek, B., & Kratz, F. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.069 · Cited by 832
Self-citationNanotechnology in cancer therapeutics: bioconjugated nanoparticles for drug delivery
Sinha, R., Kim, G. J., Nie, S., & Shin, D. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0141 · Cited by 801
Albumin-based drug delivery: harnessing nature to cure disease
Larsen, M. T., Kuhlmann, M., Hvam, M. L., & Howard, K. A. (2016) · Molecular and Cellular Therapies · doi:10.1186/s40591-016-0048-8 · Cited by 683
Supramolecular Drug‐Delivery Systems Based on Polymeric Core–Shell Architectures
Haag, R. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200301694 · Cited by 591
Rabbani, G., & Ahn, S. N. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2018.11.053 · Cited by 505
Contribution of Linker Stability to the Activities of Anticancer Immunoconjugates
Alley, S. C., Benjamin, D. R., Jeffrey, S. C., Okeley, N. M., Meyer, D. L., Sanderson, R. J., & Senter, P. D. (2008) · Bioconjugate Chemistry · doi:10.1021/bc7004329 · Cited by 479
Liu, Z., & Chen, X. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00158g · Cited by 419
Biomacromolecules as carriers in drug delivery and tissue engineering
Zhang, Y., Sun, T., & Jiang, C. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2017.11.005 · Cited by 416
Interactive Association of Drugs Binding to Human Serum Albumin
Yang, F., Zhang, Y., & Liang, H. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15033580 · Cited by 376
Clinical impact of serum proteins on drug delivery
Kratz, F., & Elsadek, B. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.028 · Cited by 375
Self-citationOettl, K., & Stauber, R. E. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707251 · Cited by 357
A clinical update of using albumin as a drug vehicle — A commentary
Kratz, F. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.013 · Cited by 334
Self-citationTijink, B. M., Laeremans, T., Budde, M., Walsum, M. S.-V., Dreier, T., de Haard, H. J., Leemans, C. R., & van Dongen, G. A. M. S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2384 · Cited by 305
Sand, K. M. K., Bern, M., Nilsen, J., Noordzij, H. T., Sandlie, I., & Andersen, J. T. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00682 · Cited by 304
Pharmaceutical Strategies Utilizing Recombinant Human Serum Albumin
Tuan Giam Chuang, V., Kragh-Hansen, U., & Otagiri, M. (2002) · Pharmaceutical Research · doi:10.1023/a:1015396825274 · Cited by 295
Kratz, F., Warnecke, A., Scheuermann, K., Stockmar, C., Schwab, J., Lazar, P., Drückes, P., Esser, N., Drevs, J., Rognan, D., et al. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020276c · Cited by 275
Self-citationThe protein corona and its effects on nanoparticle-based drug delivery systems
Li, H., Wang, Y., Tang, Q., Yin, D., Tang, C., He, E., Zou, L., & Peng, Q. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.05.019 · Cited by 265
Song, X., Liang, C., Gong, H., Chen, Q., Wang, C., & Liu, Z. (2015) · Small · doi:10.1002/smll.201500550 · Cited by 262
Metadata
- Authors
- Kratz, F., Müller-Driver, R., Hofmann, I., Drevs, J., & Unger, C.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-03-10
- Volume
- 43
- Issue
- 7
- Pages
- 1253-1256
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2051849794
- Cited by
- 166
- References
- 0
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.